Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to discovering, acquiring, developing, and commercializing therapeutic drugs for patients with serious diseases. The company has a portfolio of product candidates spanning various stages of development and is currently focused on auto-inflammatory and autoimmune diseases. The company has three clinical-stage product candidates, one of which is expected to enter Phase 3 clinical trials in 2018. We follow a disciplined and systematic approach, selectively identifying and acquiring product candidates with a strong biological rationale or validated mechanisms of action.